Postoperative Quality of Life in Patients with Hidradenitis Suppurativa Utilizing the Hidradenitis Suppurativa Burden of Disease Tool

Jiddu A. Guart¹, Victor V. Byers¹, Daniel C. Sasson², Brian Bassiri-Tehrani¹, Matthew Ranzer¹, Chad Purnell¹

1. Plastic Surgery, University of Illinois at Chicago, Chicago, USA 2. Plastic Surgery, Northwestern University Feinberg School of Medicine, Chicago, USA

Corresponding author: Jiddu A. Guart, jidduguart@mail.rossmed.edu

Abstract

Background

Hidradenitis suppurativa (HS) severely impacts patients' quality of life (QoL). Surgery has shown potential in improving a patient's QoL in severe disease. Previous studies have evaluated QoL after surgery, but lack a disease-specific questionnaire to better evaluate the unique burden of disease that patients with HS experience.

Objective

To measure postoperative QoL in patients with HS using a modified version of the disease-specific questionnaire, the Hidradenitis Suppurativa Burden of Disease (HSBOD) Tool.

Methods

A retrospective study was conducted using 19 patients who underwent surgery for HS. A demographic form and a 19-item disease-specific questionnaire were emailed to patients who consented to complete the survey. Patient-reported outcomes were recorded on a 0-100 scale (100 representing the highest burden of disease).

Results

Of the 24 patients that received the survey, 19 completed it in its entirety. The mean±SD Burden of Disease (BoD) score for each of the five domains assessed by the survey were: symptoms and feelings (62±27), daily activities (65±30), leisure (57±31), work and school (48±32), and personal relationships (56±27). Pearson's correlation between the number of surgeries each patient underwent and their reported BoD scores were not significant. BoD scores were significantly higher in the symptoms and feelings domain for complex closure compared to both secondary intention and split-thickness skin grafting (STSG).

Conclusion

Despite having surgery, patients with hidradenitis still report impaired QoL. Further study is ongoing to determine how these measures compare to baseline preoperative values. This instrument provides a valuable tool to determine QoL in patients with hidradenitis.

Categories: Dermatology, Plastic Surgery, Other

Keywords: hidradenitis suppurativa, quality of life, questionnaire, postoperative complications, hurley stage, hidradenitis suppurativa burden of disease (hsbod) tool, split thickness skin graft, secondary healing, complex closure

Introduction

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease that primarily affects the intertriginous areas of the body. Although the exact pathophysiology has yet to be elucidated, it is thought to be the result of an immune response following the obstruction of follicles within apocrine sweat glands [1,2]. Clinical manifestations include recurrent abscesses, sinus tract formation, scarring, and fibrosis. The characteristic pain, malodor, drainage, and chronicity of HS makes it one of the most physically and psychologically distressing dermatological diseases, impairing a patient's quality of life (QoL) [3]. In fact, studies show that patients with HS have significantly higher rates of depression, anxiety, completed suicide, and low self-esteem than the general population [4]. Additional factors that negatively impact QoL include delays in diagnosis, sexual dysfunction, and chronic pain. Furthermore, there is an inverse relationship between QoL and Hurley HS severity staging, which ranges from stage I (mild disease) to stage III (severe disease) [5].

Surgery remains the treatment of choice for patients with severe disease, resulting in significant

Review began 01/26/2021

Review ended 02/03/2021

Published 02/06/2021

© Copyright 2021

Guart et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

How to cite this article

Guart J A, Byers V V, Sasson D C, et al. (February 06, 2021) Postoperative Quality of Life in Patients with Hidradenitis Suppurativa Utilizing the Hidradenitis Suppurativa Burden of Disease Tool. Cureus 13(2): e13172. DOI 10.7759/cureus.13172

improvement in QoL, decreases in recurrence, and in some cases, remission of disease [6,7]. Recurrences may still occur in severe recalcitrant cases, and the disease burden is not always entirely eliminated. Therefore, improving QoL is a critical goal of surgery. A number of studies have been performed assessing the influence of various medical treatment modalities on patient QoL, but few with regards to surgery. Of the investigations that have been done, the generic Dermatology Life Quality Index (DLQI) was used [6,8]. Our group sought to offer insight into surgical outcomes for HS with a modification of the Hidradenitis Suppurativa Burden of Disease (HSBOD) tool [9]. The HSBOD tool has been shown to strongly correlate with the DLQI's overall ability to assess QoL, while better assessing certain aspects of QoL that are uniquely affected in HS such as personal relationships and work/school activities. A secondary aim of this study was to compare various surgical treatment modalities and how these affect postoperative QoL.

Materials And Methods

A retrospective survey was administered to patients being treated for HS at a tertiary care center from April to June, 2020. Subjects were included if they underwent surgery for the treatment of their HS within the past 15 years by an American Board of Plastic Surgery-certified plastic surgeon and had completed surgical treatment. Subjects were excluded if they did not speak or read in English, were lost to followup, or were continuing to undergo or had planned surgical treatments for HS.

The survey used in this study was the 19-question modified HSBOD (mHSBOD) tool with responses recorded using a visual analog scale (VAS) (Figure 1). Using an online data collection tool, Research Electronic Data Capture (REDCap), a demographics questionnaire and the mHSBOD survey were distributed via email, and patient responses were recorded. After the initial distribution of the survey, follow-up calls were made weekly over the span of three months and the survey was re-sent upon patient request.

Confidential

Page 1

Burden of Disease Tool

Please complete the survey below.
Thank you!

NOTE: Please respond to these questions as to how you feel after receiving surgery. How did your hidradenitis suppurativa affect your life? (Drag the slider to the appropriate location on the scale below):

1) How often have you experienced pain from your hidradenitis suppurativa?

NeverAll The Time

(Place a mark on the scale above)

2) How often has ulceration (skin making an ulcer or open sore) been a problem from your hidradenitis suppurativa?

NeverAll The Time

(Place a mark on the scale above)

3) How often has drainage of fluid/pus been a problem for your hidradenitis suppurativa?

NeverAll The Time

(Place a mark on the scale above)

4) How often has odor/smell been a problem from your hidradenitis suppurativa?

NeverAll The Time

(Place a mark on the scale above)

5) How often has scarring been a problem from your hidradenitis suppurativa?

NeverAll The Time

(Place a mark on the scale above)

6) How often has hidradenitis suppurativa affected your intimacy or sexual activity?

NeverAll The Time

(Place a mark on the scale above)

7) How often has hidradenitis suppurativa affected your body self-image (how you feel about your body)?

NeverAll The Time

(Place a mark on the scale above)

8) How often has hidradenitis suppurativa contributed to feelings of shame or embarrassment?

NeverAll The Time

(Place a mark on the scale above)

9) How often have you avoided physical contact (touching, intimacy, etc) because of your hidradenitis suppurativa?

NeverAll The Time

(Place a mark on the scale above)

09/08/2020 4:19pm

projectredcap.org

REDCap

Confidential

Page 2

10) How often has hidradenitis suppurativa affected your clothing choices?

NeverAll The Time

(Place a mark on the scale above)

11) How often has hidradenitis suppurativa impacted your toileting and personal hygiene?

NeverAll The Time

(Place a mark on the scale above)

12) How often has hidradenitis suppurativa interfered with school or work?

NeverAll The Time

(Place a mark on the scale above)

13) How often has hidradenitis suppurativa interfered with recreational activities or hobbies?

NeverAll The Time

(Place a mark on the scale above)

14) How often has hidradenitis suppurativa interfered with basic activities (walking, sitting)?

NeverAll The Time

(Place a mark on the scale above)

PLEASE ANSWER THE NEXT QUESTIONS BASED ON THE ENTIRE TIME YOU HAVE HAD HIDRADENITIS SUPPURATIVA:

15) How often has hidradenitis suppurativa affected personal intimate relationships (for example dating, marriage)?

NeverAll The Time

(Place a mark on the scale above)

16) Has hidradenitis suppurativa affected your decision to have or consider having children?

Not At AllCompletely

(Place a mark on the scale above)

17) How often has hidradenitis suppurativa contributed to a depressed mood or feeling of anxiety / worry?

NeverAll The Time

(Place a mark on the scale above)

18) How often has hidradenitis suppurativa impacted your ability to hold or find a job?

NeverAll The Time

(Place a mark on the scale above)

19) How often has hidradenitis suppurativa impacted your finances (including all sources, such as financial loss from costs of treatment, lost work/wages, etc)?

NeverAll The Time

(Place a mark on the scale above)

09/08/2020 4:19pm

projectredcap.org

REDCap

FIGURE 1: Modified Hidradenitis Suppurativa Burden of Disease Tool

Patient age, sex, race, annual income, tobacco use, alcohol use, and body mass index (BMI) were obtained via a demographic survey. Hurley stage for each patient was assessed using information from physical exams and direct classification by their dermatologists and plastic surgeons found in the electronic medical record. Additionally, the following data were collected: number of operations received by each patient, number of surgical sites treated, surgical site locations, types of wound closure, types of dressing used, follow-up intervals, time to wound closure (TTWC), recurrence rates and their management, and complications. Each patient was treated with wide excision of the diseased tissues with varying types of closure techniques, including complex closure, healing by secondary intention, or delayed split-thickness skin grafting (STSG).

In its original description, the first 14 questions of the HSBOD tool were used to measure QoL in the last four weeks. However, in order to better evaluate surgery's impact on QoL, we adapted the first 14 questions of the HSBOD to assess patient QoL following surgery and kept the final five questions as assessment of lifetime impact on QoL, thereby creating the aforementioned mHSBOD (Figure 1). Patients scored each item on a VAS from 0, meaning no burden of disease (BoD), to 100, meaning maximum BoD. BoD was assessed across 5 QoL domains using the respective questions as follows: symptoms and feelings (questions 1-9 and 17), daily activities (questions 10 and 13), leisure (questions 11, 13, and 14), work/school (questions 12, 18, and 19),

2021 Guart et al. Cureus 13(2): e13172. DOI 10.7759/cureus.13172

2 of 11

and personal relationships (questions 6-9, 15, and 16).

Descriptive statistics were used to evaluate the study data. Pearson’s correlation between the number of surgeries each patient individually received and their reported BoD scores for each of the 5 domains were measured. Pearson’s correlation was measured between the number of surgical sites per patient and the patient reported BoD score for each of the 5 domains. A Mann-Whitney U test was used to compare patient reported BoD scores in each domain by differences in treatment.

Results

Of the 24 surveys distributed, 19 were completed in full, yielding a response rate of 79%. Participants had a mean ± SD age of 41 ± 14 years and the majority of respondents were female (15/24), mean BMI was 37 ± 10 and all patients were Hurley stage 2 or greater with the majority being stage 3 (17/24) (Table 1).

	N=19
Age (years ± SD)	41.105 ± 13.58
Gender	
Male (%)	4 (21%)
Female (%)	15 (79%)
Body Mass Index (kg/m2)	36.985 ± 9.4171
Smoking status	
Current smoker	3 (15%)
Former smoker	4 (21%)
Never smoked	12 (63%)
Hurley stage distribution	
II	2 (10%)
III	17 (90%)

TABLE 1: Patient Characteristics

An overview of surgical outcomes are shown in Tables 2-3. The majority of surgical sites were the axilla (n=21, 34.4%) followed by the groin (n=17, 27.9%). Of the total number of surgical sites, the majority were closed using complex closure technique (n=45, 61.6%). Of the 18 surgical sites that underwent healing by secondary intention (24.7%), 17 used a betadine wet-to-dry dressing (44.7%), followed by calcium alginate (n=9, 23.7). The mean follow-up length was 15 ± 23 months. Twelve surgical sites had recurrence and 11 of these were managed by a return to the operating room (RTOR). Of the complications that occurred, wound dehiscence in patients that underwent complex closure was the most common (n=24, 28.6%) followed by bleeding complications, which were controlled with bedside maneuvers (i.e. suture ligation, cautery, point pressure). There was no significant difference in complication rates between complex closure and secondary intention (P=0.117).

	Total # of patients (%) (N=19)
Number of diseased sites	
One	4 (21.1)
Two	5 (26.3)
Three	1 (5.3)
Four	4 (21.1)
Five	1 (5.3)
Six	2 (10.5)
Seven	1 (5.3)
Eight	1 (5.3)
	Total # of surgical sites (%) (N=61)
Surgical Sites	
Axilla	21 (34.4)
Groin	17 (27.9)
Other	9 (14.8)
Perineum	8 (13.1)
Breast/Chest	6 (9.8)
Type of Closure	
Primary closure	45 (65.2)
Secondary intention	18 (26.1)
Split thickness skin graft (STSG)	6 (8.7)
Dressing Type Used	(secondary intention only)
Betadine wet-to-dry	17 (44.7)
Calcium alginate	9 (23.7)
Saline wet-to-dry	4 (10.5)
Silvadene	4 (10.5)
Bacitracin	4 (10.5)

TABLE 2: Surgical Location and Methods

Number of diseased sites for each patient, location of surgical sites, type of closure technique, and dressing types used in patients treated with secondary intention.

	Complex Closure	Secondary Intention	STSG	Total
Total # of surgical sites	45	18	6	69
Recurrence				
Total (rate)	9 (20)	3 (16.7)	0 (0)	12 (17.4)
Timeframe: index operation to recurrence (months)	15.3 ± 11.7	11.7 ± 2.6	-	-
Management of recurrence				
Silver nitrate	1 (2.2)	0 (0)	0 (0)	1 (1.4)
Return to Operating Room	8 (17.7)	3 (16.7)	0 (0)	11 (15.9)
Complications				
Minor Bleeding	20 (44.4)	9 (50)	1 (16.6)	30 (43.4)
RTOR	6 (13.3)	6 (33.3)	0 (0)	12 (17.4)
Transfusion	3 (6.7)	4 (22.2)	0 (0)	7 (10.1)
Infection	7 (15.6)	5 (27.8)	0 (0)	12 (17.4)
Wound dehiscence	23 (51.1)	0 (0)	1 (16.7)	24 (34.8)
Total	59 (131)*	24 (133)*	2 (33.3)	85 (123)*
Time to Wound Closure Mean (months) ± SD	3.92±5.56	-	12.38±12.90	-
* values greater than 100% because some sites had multiple complications				

TABLE 3: Complications and Recurrence: Complex Closure, Secondary Intention, and Split-thickness Skin Graft

Comparison of recurrence and complication data for each closure technique. Comparison of time to wound closure (TTWC) between complex closure and split-thickness skin graft (STSG).

The mean scores for each of the 5 domains were as follows: symptoms and feelings (62 ± 27), daily activities (65 ± 30), leisure (57 ± 31), work and school (48 ± 32), and personal relationships (56 ± 27) (Figure 2).

Mean BoD scores for those who underwent complex closure were significantly higher than both secondary intention and STSG in the symptoms and feelings domain (70.88 ± 30.68 vs. 51.02 ± 38.13 and 32.45 ± 30.13 respectively, $P = 0.035$) (Table 4). To control for the higher rate of complications in the complex closure group, a subgroup analysis compared patients who underwent complex closure with or without complications and no significant difference was found (Figure 5). The mean TTWC for those that underwent complex closure was 3.92 ± 5.56 months and STSG was 12.38 ± 12.90 months ($P = 0.118$). Correlation of number of surgical sites with BoD scores in each domain were: symptoms & feelings ($r = -0.18$), personal relationships ($r = -0.26$), Daily activities ($r = -0.34$), leisure ($r = -0.19$), work/school ($r = 0.15$) (Figure 4).

	Complex Closure	Secondary Intention	STSG	
Total # of patients	12	5	2	
	Mean BoD Score $\pm$ SD			P [^]
QoL Domain				
Symptoms and Feelings	70.88 $\pm$ 30.68	51.02 $\pm$ 38.13	32.45 $\pm$ 30.13	0.035
Personal Relationships	60.08 $\pm$ 36.68	55.77 $\pm$ 40.90	55.77 $\pm$ 40.90	0.622
Daily Activities	74.58 $\pm$ 29.66	55.40 $\pm$ 46.49	39.75 $\pm$ 40.19	0.343
Leisure	62.18 $\pm$ 37.25	44.53 $\pm$ 36.70	49.67 $\pm$ 32.88	0.376
Work and School	45.47 $\pm$ 36.93	52.27 $\pm$ 42.16	53.83 $\pm$ 50.71	0.925

TABLE 4: Closure Techniques and Burden of Disease Scores in each Quality of Life Domain

Comparison of mean burden of disease (BoD) scores between closure techniques (complex closure, secondary intention, and STSG) in each of the five quality of life (QoL) domains.

FIGURE 3: Complex Closure Subgroup Analysis

Bar graph comparing average BoD scores in each domain between patients treated with complex closure without subsequent complications vs. complex closure with subsequent complications. Mann-Whitney U was performed and P-values are labeled above.

FIGURE 4: Relationship between Burden of Disease and Number of Surgical Sites

Line graph depicting the relationship between burden of disease (BoD) scores and number of surgical sites for each of the five quality of life (QoL) domains.

We performed a Mann-Whitney U test to compare BoD scores for each of the five QoL domains between patients who underwent surgical treatment at a single site (n=4) vs. multiple sites (n=15). We found no significant difference between the mean BoD scores for those who had multiple sites vs. a single surgical site for all QoL domains (Figure 5). Comparison between staged and non-staged reconstruction resulted in non-significant differences between groups in all domains (Figure 6).

FIGURE 5: Average Burden of Disease Score for Each Domain: Single Surgical Site vs. Multiple Surgical Sites

Bar graph depicting burden of disease (BoD) scores for a single surgical site vs multiple surgical sites. A Mann-Whitney U was performed and P-values are labeled above.

FIGURE 6: Average Burden of Disease Score in Each Domain: Staged vs. Non-Staged

Bar graph comparing the BoD scores in the five QoL domains for patients undergoing staged vs non-staged procedures. A Mann-Whitney U was run to compare staged and non-staged procedures in each of the five domains, the P-values for each are depicted above.

Discussion

This retrospective cohort study utilized the mHSBOD questionnaire to study postoperative QoL in patients suffering from HS. Our study found that patients reported continued moderate BoD postoperatively, with scarring and self-image reported as most impacted domains. Additionally, we found no correlation between the number of individual surgeries received by each patient and their reported BoD.

Prens et al. found that patients with HS who were treated with surgery had DLQI scores which returned to baseline at their six-month follow-up interval, and Posch et al. found a significant decrease in the DLQI scores of patients treated with surgery after six months [6,10]. Extrapolating from this, one would assume that patients in our study would be at this improved level of QoL. However, given that preoperative values were not tested in this study, this cannot be necessarily assumed. Kouris et al. evaluated 22 unoperated patients with Hurley Stage III disease and found a mean DLQI of 19.32 [11]. In a different study, Prens et al. found that the mean post-operative DLQI score at six months was 15.6, with scores above 10 indicating severely impacted QoL. So perhaps the burden of disease is simply very high in a surgical HS population, and while surgery improves this, it does not resolve all of the QoL issues associated with the disease.

It follows that a moderate amount of impairment was found in every domain of the questionnaire. Beyond the possibilities discussed above, we feel there may be several reasons for this. Firstly, while all of the areas of surgical hidradenitis may have been treated for these patients, it is still possible that they struggle with continued lower-stage lesions that have an effect on QoL. Unfortunately, the study design does not have adequate granularity to capture the presence of these areas. Another possibility is that chronic HS results in long-lasting effects, even after the disease burden is decreased. The patients in our cohort have been affected by HS for over a decade on average, and therefore the lasting psychological impact may influence their perception of themselves and impact the scores reported, regardless of surgery [12]. Future studies are needed to evaluate the effects of multidisciplinary management in surgical HS, including psychotherapy [13,14]. Furthermore, scarring (item 5) and self-image (item 7) resulting from HS had the largest BoD postoperatively (74.84 and 70.85 respectively). Scarring is a permanent result of either surgery or HS and this BoD may likely be present regardless of surgical treatment.

In our patient group, recurrence occurred at 19% (n=12) of surgical sites. This is a lower recurrence rate compared to studies which used similar excision methods reporting recurrence rates between 27%-29% [15,16]. It is also possible that the patient definition of recurrence is different than the surgeons. Patients in this study were not re-examined after distribution of the survey unless it was part of routine follow up, and therefore potential mild recurrence may have been missed. In any case, we found that there was no significant correlation between the number of surgeries performed on each patient and the impact on their BoD scores. This is significant in that many patients with severe disease experience recurrence and undergo several operations. It seems from these data that once a surgical endpoint has been reached in HS, BoD is similar.

We found that in regards to symptoms and feelings, patients that treated with healing by secondary intention or STSG reported significantly lower BoD ($P < 0.05$) compared with complex closure. This is somewhat counterintuitive - one might expect lower BoD scores in patients with complex closure due to the immediate and definitive closure of the wound at the time of the operation. Our findings could be due to the fact that HS has a predilection for intertriginous areas. These high-mobility areas predispose complex closures to complications such as dehiscence, limitation of range of motion, and scarring, possibly leading to lasting impacts on QoL [17]. Certainly, complication rates were higher amongst patients treated with complex closure in this cohort (70% versus 30% for secondary healing). In order to determine if the complications were the cause of increased BoD, a subgroup analysis was performed, which did not show significant differences amongst complex closure patients with and without a complication. However, this study is likely underpowered for this type of subgroup analysis. One would also think that increased time to wound closure would negatively affect QoL, but this did not seem to be correlated. Perhaps if the study timepoint would be during the healing process, wounds that took longer to close would cause a greater BoD, but once healed all wounds reach a similar endpoint. TTWC was still much shorter in patients who had a complex closure versus a skin graft or secondary intention healing, even with dehiscence complications.

This study illustrates the usefulness of the HSBOD tool to assess disease-related BoD in HS. Such research can open doors for clinicians to better guide treatment and form protocols, with superior evidence in regards to improving patient QoL. In addition to the disease-specific nature of the questionnaire, the short 19-item format is beneficial to the in-office practice of assessing patient QoL when compared to conventional, lengthier QoL assessment methods [8].

This study was limited by its retrospective nature, small sample size, and single time point of the survey. Given our small sample size, the comparisons between surgical techniques, single surgical site vs. multiple surgical sites, and staged vs. non-staged operations are almost certainly underpowered. We intend to expand this pilot study with a larger prospective study that follows patients throughout the surgical process. In addition, the lack of a preoperative baseline measurement to compare against postoperative QoL is a major

limitation - it is possible that subjects in this study actually did have a significant improvement in QoL but started with very poor baseline scores [18]. Despite these limitations, our finding of moderately impacted BoD still remaining even after completion of surgical therapy is important for discussion with patients planning on undergoing surgery.

Conclusions

Despite surgical intervention for HS, patient QoL is still impacted across the five domains assessed by the mHSBOD tool. The number of surgeries a patient receives does not have a significant correlation on their reported BoD. Patients who undergo complex closure for HS have a higher postoperative BoD than those treated with STSG or secondary intention healing. The mHSBOD tool is a useful tool to define the disease-specific effects of HS on QoL.

Additional Information

Disclosures

Human subjects: All authors have confirmed that this study did not involve human participants or tissue.

Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue.

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

I share first authorship with Victor Byers.

References

1. Seyed Jafari SM, Hunger RE, Schlapbach C: Hidradenitis suppurativa: current understanding of pathogenic mechanisms and suggestion for treatment algorithm. *Front Med.* 2020, 7:68. [10.3389/fmed.2020.00068](#)
2. Napolitano M, Megna M, Timoshchuk EA, Patruno C, Balato N, Fabbrocini G, Monfrecola G: Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment. *Clin Cosmet Investig Dermatol.* 2017, 10:105-115. [10.2147/CCID.S111019](#)
3. Wolkenstein P, Loundou A, Barrau K, Auquier P, Revuz J: Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. *J Am Acad Dermatol.* 2007, 56:621-623. [10.1016/j.jaad.2006.08.061](#)
4. Patel KR, Lee HH, Rastogi S, et al.: Association between hidradenitis suppurativa, depression, anxiety, and suicidality: a systematic review and meta-analysis. *J Am Acad Dermatol.* 2020, 83:737-744. [10.1016/j.jaad.2019.11.068](#)
5. Senthilnathan A, Kolli SS, Cardwell LA, Richardson IM, Feldman SR, Pichardo RO: Even mild hidradenitis suppurativa impairs quality of life. *Br J Dermatol.* 2019, 181:838-839. [10.1111/bjd.17928](#)
6. Prens LM, Huizinga J, Janse IC, Horváth B: Surgical outcomes and the impact of major surgery on quality of life, activity impairment and sexual health in hidradenitis suppurativa patients: a prospective single centre study. *J Eur Acad Dermatol Venereol.* 2019, 33:1941-1946. [10.1111/jdv.15706](#)
7. Kofler L, Schweinzer K, Heister M, Kohler M, Breuninger H, Häfner HM: Surgical treatment of hidradenitis suppurativa: an analysis of postoperative outcome, cosmetic results and quality of life in 255 patients. *J Eur Acad Dermatol Venereol.* 2018, 32:1570-1574. [10.1111/jdv.14892](#)
8. Chernyshov PV, Zouboulis CC, Tomas-Aragones L, et al.: Quality of life measurement in hidradenitis suppurativa: position statement of the European Academy of Dermatology and Venereology task forces on Quality of Life and Patient-Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa. *J Eur Acad Dermatol Venereol.* 2019, 33:1633-1643. [10.1111/jdv.15519](#)
9. Pinard J, Vleugels RA, Joyce C, Merola JF, Patel M: Hidradenitis suppurativa burden of disease tool: pilot testing of a disease-specific quality of life questionnaire. *J Am Acad Dermatol.* 2018, 78:215-217. [10.1016/j.jaad.2017.08.030](#)
10. Posch C, Monshi B, Quint T, Vujic I, Lilgenau N, Rappersberger K: The role of wide local excision for the treatment of severe hidradenitis suppurativa (Hurley grade III): retrospective analysis of 74 patients. *J Am Acad Dermatol.* 2017, 77:123-129. [10.1016/j.jaad.2017.01.055](#)
11. Kouris A, Platsidaki E, Christodoulou C, et al.: Quality of life and psychosocial implications in patients with hidradenitis suppurativa. *Dermatology.* 2016, 232:687-691. [10.1159/000453355](#)
12. Janse IC, Deckers IE, van der Maten AD, et al.: Sexual health and quality of life are impaired in hidradenitis suppurativa: a multicentre cross-sectional study. *Br J Dermatol.* 2017, 176:1042-1047. [10.1111/bjd.14975](#)
13. Veraldi S, Guanzioli E, Benzecry V, Nazzaro G: Multidisciplinary approach for hidradenitis suppurativa patients. *G Ital Dermatol Venereol.* 2018, 2:18-19. [10.23736/S0392-0488.17.05779-0](#)
14. Kirby JS, Butt M, Esmann S, Jemec GBE: Association of resilience with depression and health-related quality of life for patients with hidradenitis suppurativa. *JAMA Dermatol.* 2017, 153:1263-1269. [10.1001/jamadermatol.2017.3596](#)
15. Blok JL, Boersma M, Terra JB, et al.: Surgery under general anaesthesia in severe hidradenitis suppurativa: a study of 363 primary operations in 113 patients. *J Eur Acad Dermatol Venereol.* 2015, 29:1590-1597. [10.1111/jdv.12952](#)
16. Ritz JP, Runkel N, Haier J, Buhr HJ: Extent of surgery and recurrence rate of hidradenitis suppurativa. *Int J*

- Colorectal Dis. 1998, 13:164-168. [10.1007/s003840050159](https://doi.org/10.1007/s003840050159)
17. Rompel R, Petres J: Long-term results of wide surgical excision in 106 patients with hidradenitis suppurativa. *Dermatol Surg.* 2000, 26:638-643. [10.1046/j.1524-4725.2000.00043.x](https://doi.org/10.1046/j.1524-4725.2000.00043.x)
 18. Bishop PA, Herron RL: Use and misuse of the likert item responses and other ordinal measures . *Int J Exerc Sci.* 2015, 8:297-302.